Seven Fleet Capital Management LP Makes New $261,138 Investment in Amylyx Pharmaceuticals, Inc. $AMLX

Seven Fleet Capital Management LP acquired a new position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 14,540 shares of the company’s stock, valued at approximately $261,138.

A number of other hedge funds have also recently modified their holdings of AMLX. Meeder Asset Management Inc. bought a new position in Amylyx Pharmaceuticals in the 4th quarter worth about $25,000. KBC Group NV acquired a new position in Amylyx Pharmaceuticals in the first quarter valued at $26,000. California State Teachers Retirement System acquired a new stake in Amylyx Pharmaceuticals in the second quarter valued at $28,000. State of Wyoming acquired a new position in Amylyx Pharmaceuticals during the second quarter worth about $40,000. Finally, Caitong International Asset Management Co. Ltd boosted its holdings in Amylyx Pharmaceuticals by 954.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,859 shares of the company’s stock worth $47,000 after purchasing an additional 3,493 shares in the last quarter. Institutional investors own 95.84% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on AMLX shares. Robert W. Baird increased their price objective on shares of Amylyx Pharmaceuticals from $28.00 to $52.00 and gave the company an “outperform” rating in a research report on Wednesday, August 19th. Wolfe Research raised shares of Amylyx Pharmaceuticals to a “strong-buy” rating in a research note on Monday, August 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research report on Wednesday, August 5th. Mizuho lifted their price objective on Amylyx Pharmaceuticals from $30.00 to $42.00 and gave the stock an “outperform” rating in a report on Tuesday, August 18th. Finally, Wall Street Zen lowered shares of Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $36.50.

Insider Buying and Selling at Amylyx Pharmaceuticals

In other news, insider Gina Mazzariello sold 15,000 shares of the company’s stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $18.32, for a total value of $274,800.00. Following the transaction, the insider owned 194,090 shares of the company’s stock, valued at approximately $3,555,728.80. This represents a 7.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 10.90% of the stock is owned by company insiders.

Amylyx Pharmaceuticals Trading Down 6.6%

NASDAQ AMLX traded down $2.44 on Friday, hitting $34.74. 1,361,385 shares of the company traded hands, compared to its average volume of 1,683,186. The business’s 50 day moving average price is $22.15 and its 200-day moving average price is $17.37. Amylyx Pharmaceuticals, Inc. has a 52-week low of $9.15 and a 52-week high of $41.14. The company has a market capitalization of $3.87 billion, a price-to-earnings ratio of -24.29 and a beta of -0.21.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.03). As a group, sell-side analysts predict that Amylyx Pharmaceuticals, Inc. will post -1.48 earnings per share for the current year.

About Amylyx Pharmaceuticals